Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional) | PAR 21 059

Frequently Asked Questions (FAQs)

What is the title and identifier of this funding opportunity?

The opportunity is titled "Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)" and is identified as PAR-21-059.

Which agency is offering this program?

This is a National Institutes of Health (NIH) program announcement.

What is the main goal of this funding opportunity?

The goal is to support rigorous clinical validation of a promising neurological or neuromuscular biomarker in the real clinical population where it is intended to be used, using validation practices aligned with FDA expectations.

What does "clinical validation" mean in the context of this announcement?

Clinical validation here means generating strong, clinically grounded evidence about how well the biomarker performs in its intended use setting and target patient population, especially evidence that clarifies how accurately the biomarker identifies or rules out a condition (or a clinically meaningful state related to that condition).

What types of performance evidence are emphasized?

The announcement emphasizes evidence of clinical predictive performance, particularly positive predictive value (PPV) and negative predictive value (NPV), so users can understand how accurately the biomarker can confirm or exclude the relevant condition or state in the intended population and context of use.

Is this opportunity meant for biomarker discovery or early feasibility studies?

No. It is explicitly not meant for early discovery or basic feasibility work. It assumes the biomarker has already been identified and that key preparatory steps are already complete before applying.

What must already be in place before applying?

Based on the description, three major prerequisites are expected: (1) the candidate biomarker has already been identified with strong rationale and preliminary evidence; (2) the method used to measure the biomarker already exists and has been analytically validated; and (3) the clinical or research need and a plausible context of use are clearly defined.

What does it mean that the measurement method must be "analytically validated"?

It means the assay or measurement technology has already been shown to be technically reliable, with appropriate evidence and controls for characteristics such as accuracy, precision, sensitivity, specificity, reproducibility, and quality control procedures.

What is a "context of use" and why does it matter here?

A context of use is a clear description of how the biomarker would be used in practice. The program expects applicants to define a plausible context of use (for example, diagnosis, prognosis, patient stratification, monitoring disease progression, or measuring response to treatment) because the clinical validation work is meant to show performance in that intended real-world setting.

What kinds of biomarker uses are mentioned as examples?

Examples provided include diagnosis, prognosis, patient stratification, monitoring disease progression, and measuring response to treatment.

What is the award mechanism for this opportunity?

The mechanism is a U44 cooperative agreement.

What does a U44 cooperative agreement imply compared to a typical grant?

A cooperative agreement indicates more hands-on involvement by NIH staff during the project period, including substantial scientific and programmatic involvement such as milestone oversight, alignment with program goals, and active collaboration to keep the project focused on generating validation-grade evidence.

Does the project have to include a clinical trial?

No. The opportunity is labeled "Clinical Trial Optional," meaning a clinical trial component may be proposed if appropriate for validation, but conducting a clinical trial is not required for eligibility.

Who is this funding opportunity primarily intended for?

Eligibility is focused on small businesses, consistent with an SBIR/STTR-style translational pipeline where companies advance tools or products toward real-world adoption.

Are foreign institutions eligible to apply?

No. Foreign institutions are not eligible to apply.

Can a U.S. organization apply if it has a non-U.S. component?

Non-U.S. components of U.S. organizations are also not eligible, as described in the opportunity summary.

Are any international activities allowed at all?

The summary notes that "foreign components" as defined in the NIH Grants Policy Statement may be allowed. This typically means a U.S. applicant may be able to include limited, well-justified foreign activities or collaborations if they meet NIH policy requirements and are clearly necessary for the project.

What disease areas does this opportunity target?

It targets biomarkers relevant to neurological or neuromuscular disorders.

What is the expected deliverable from projects funded under this announcement?

The expected deliverable is a rigorous, FDA-consistent demonstration of the biomarker's clinical predictive performance in the intended patient population and use setting. The emphasis is on validation-grade evidence rather than another association study.

How is this program positioned in the biomarker development pipeline?

It is described as a bridge between a biomarker that looks promising in preliminary work and the stage where it has been convincingly validated in the clinical population where it is intended to be used.

What downstream uses are mentioned for a successfully validated biomarker?

The summary mentions that strong validation evidence can support downstream steps such as broader clinical adoption, integration into clinical trials, or advancement toward regulatory qualification, depending on the biomarker and intended use.

What is the CFDA number associated with this opportunity?

The opportunity is associated with CFDA number 93.853.

What general funding category is this opportunity listed under?

The funding activity is categorized under health.

When was the program created and what was the listed closing date?

The program was created on 2020-11-19, and the original closing date listed was 2023-08-07.

What kind of evidence standard does the announcement encourage?

It encourages rigorous validation practices aligned with FDA expectations, with an emphasis on clinically meaningful performance metrics (including PPV and NPV) in the intended use setting.